 WOBURN, Mass., Oct. 01, 2021 GLOBE NEWSWIRE -- Replimune Group, Inc. Nasdaq: REPL, a biotechnology company developing oncolytic immuno-gene therapies derived from its ImmulyticTM platform, today announced four poster presentations at the upcoming Society for Immunotherapy of Cancers SITC 36th Annual Meeting being held November 10-14, 2021. 